Introduction {#S1}
============

Transthyretin (TTR) variant amyloidosis (ATTRv) is an autosomal dominant disease characterized by the formation and storage of amyloid aggregates in many organs, mostly causing an axonal sensory-motor neuropathy, cardiomyopathy, gastrointestinal dysfunction, and dysautonomia. More than 120 TTR variants (TTRv) are known with several thousand cases worldwide, and organ involvement and clinical symptoms widely depend on the type of mutation ([@B1]). A staging system classifies patients into three stages based on severity of symptoms and the extent of disease progression, being stage 1 for symptomatic subjects with unimpaired walking, stage 2 for need of mono- or bilateral walking assistance, and stage 3 for patients relying on a wheelchair to move around. Stage 0 is an asymptomatic stage for subjects who have a TTRv but do not show yet any symptoms of the disease ([@B3]). Based on phase 3 clinical trials, the effectiveness of current treatment options is limited to stage 1 and 2 ATTRv patients ([@B44]), so that regular follow-ups are done in asymptomatic carriers to monitor the appearance of the first symptoms and to start treatment ([@B37]). Several neurophysiological and cardiological markers of early damage have been recently proposed ([@B22]; [@B31]; [@B50]). At the moment, no biomarker is available to document the progression from an asymptomatic to symptomatic status.

MicroRNAs (miRNAs) are small (20--25 nucleotides), evolutionary conserved, non-coding RNAs which negatively regulate gene expression by binding to the 3'-untranslated region of target mRNAs in a sequence-specific manner, leading to either mRNA degradation or translational repression. They can also positively regulate gene expression by repression of several negative regulators ([@B26]). They are expressed specifically in different tissues but circulating miRNAs have been recognized in human plasma and serum, since they are passively leaked or actively transported from cells. More specifically, miRNAs play key roles in vital biological processes such as cell division and death, metabolism, intracellular signaling, immunity, and cell movement ([@B7]; [@B38]; [@B39]; [@B36]). In the last years, circulating miRNAs emerged as an interesting new class of biomarkers, being easily measured using common laboratory techniques, with potential clinical relevance for diagnosis and prognosis, to predict responders from non-responders to a given treatment, or even as therapeutic targets ([@B18]; [@B35]; [@B28]; [@B13]). We performed a pilot study to determine whether circulating miRNAs could be identified in the blood of ATTRv patients and if so, whether they are linked to disease stage.

Materials and Methods {#S2}
=====================

Blood samples were obtained from 10 ATTRv patients (stage 1 or 2), 10 asymptomatic carriers of TTRv, 5 patients with axonal-type Charcot-Marie-Tooth (CMT) disease type 2 and 5 patients with CMT type 1A as pathological controls, and 10 healthy controls (HC) ([Table 1](#T1){ref-type="table"}). The ATTRv patients and the asymptomatic subjects carried the following TTR mutations: Glu89Gln (n. 4 and n. 4, respectively), Phe64Leu (n. 4 and n. 4), Thr49Ala (n. 2 and n. 2) ([@B33]). All 10 symptomatic patients presented neuropathy, 5/10 had cardiopathy, and 7/10 had dysautonomia. All were on treatment with tafamidis. Patients had no concomitant major disease, such as diabetes, hypertension, ischemic heart disease, neoplasm, cerebrovascular disease, etc. Local ethics committee approved the study and all subjects gave written informed consent.

###### 

Populations studied.

                             ATTRv patients   Asymptomatic TTRv carriers   CMT patients   Healthy controls
  -------------------------- ---------------- ---------------------------- -------------- ------------------
  **Discovery set**                                                                       
  No.                        10               10                           10             10
  Male/female                5/5              4/6                          6/4            5/5
  Age (years)                52.8 ± 6.3       44.0 ± 7.0                   43.5 ± 18.7    48.0 ± 7.5
  Disease duration (years)   6.7 ± 4.0        NA                           17.0 ± 14.8    NA
  **Validation set**                                                                      
  No.                        24               23                           --             --
  Male/female                15/9             10/13                        --             --
  Age (years)                63.7 ± 12.1      49.1 ± 8.3                   --             --
  Disease duration (years)   7.7 ± 4.9        NA                           --             --

Mean ± SD; NA, not applicable.

Blood samples were withdrawn by venipuncture into BD Vacutainer tubes with a gel separating serum from blood cells. The samples were centrifuged at 3500 RPM for 15 min at 4°C. Supernatant was isolated and centrifuged again to remove circulating cells or debris. Aliquots of serum were stored at −80°C, until analysis.

RNA Isolation {#S2.SS1}
-------------

Eight hundred microliter serum samples were used to extract total RNA using Qiagen miRNeasy Mini Kit (Qiagen, GmbH, Hilden, Germany), according to Qiagen Supplementary Procedure for the purification of RNA, including small RNAs. Obtained RNA was eluted in 200 μl RNAse-free water and then precipitated adding 20 μg glycogen, 0.1 volumes 3 M sodium acetate, and 2.5 volumes ice cold 100% ethanol. Following overnight incubation at --80°C, RNA was centrifuged and twice washed in ice cold 75% ethanol and resuspended in 7 μl RNAse-free water. RNA was quantified by Nanodrop.

Circulating miRNA Profiling {#S2.SS2}
---------------------------

Serum miRNA expression profile was done by nCounter Human v3 miRNA Expression Assay Kit (NanoString Technologies; Seattle, WA, United States) in an nCounter FLEX (Prep Station and Digital Analyzer) (NanoString Technologies), according to manufacturer procedures. Three microliter, containing about 100 ng of total RNA, were utilized for sample preparation. Data analysis was made through nSolver 2.6 software (NanoString Technologies). MiRNAs used as endogenous controls were chosen through global median normalization method: we computed Pearson correlation between the count means for each lane and the counts of each miRNA, identifying those miRNAs whose expression was closer to the count mean of the cartridge (miR-23a-3p, miR-1285-5p, miR-451a) ([@B12]).

Single miRNA qRT validation analysis was performed on 20 ng of total RNA by using single TaqMan^®^ MicroRNA Assays (Applied Biosystems) in a 7300 Real time PCR instrument (Thermo Fisher Scientific, Waltham, MA, United States), according to the manufacturer's instructions. Expression fold changes were calculated by the 2^--ΔΔCT^ method by using RNU6 as reference genes. All assays were performed in triplicate.

Gene Ontology and Pathway Enrichment Analysis {#S2.SS3}
---------------------------------------------

To investigate the effects of the deregulation of miRNAs, a gene ontology (GO) analysis was performed following two parallel approaches. Experimentally validated targets of upregulated miRNAs were retrieved from TarBase v7.0^[1](#footnote1){ref-type="fn"}^. The resulting list of mRNA targets was used as input for the TopGO v2.24.0 package, which analyzes the GO database. Moreover, upregulated miRNAs were submitted to the tool DIANA mirPath v3.0^[2](#footnote2){ref-type="fn"}^, which performed a pathway enrichment analysis according to the Kyoto Encyclopedia of Genes and Genomes (KEGG). DIANA mirPath was performed on experimentally validated miRNA targets retrieved from Tarbase v7.0 by appling FDR correction (*p* \< 0.05, MicroT \< 0.8) and Fisher's Exact Test (Hypergeometric Distribution).

Cell Culture {#S2.SS4}
------------

Human primary Schwann cells (SCs) (ABM Good, Richmond, Canada) were cultured in Prigrow X series medium (ABM Good) containing 10% fetal bovine serum (Gibco, Gaithersburg, MD, United States), 100 μg/ml streptomycin, and 100 IU/ml penicillin (Sigma, St. Louis, MO, United States) at 37°C in a 5% CO~2~ humidified atmosphere. The cells were subcultured every 2--3 days.

miRNA Transfections {#S2.SS5}
-------------------

miR-150-5p mimic/inhibitor (ID MC10070/MH10070; Thermo Fisher Scientific) were transfected into human primary SCs using siPORT Lipid Transfection Reagent (Thermo Fisher Scientific) according to the manufacturer's procedure. Cells were transfected with 50 nmol of oligonucleotide per well (0.5 × 10^6^ cells). Transfected cells were assayed 24 and 48 h after the transfection.

Western Blot Analysis {#S2.SS6}
---------------------

SCs samples were processed in lysis buffer (25 mM Tris/HCL, pH 7.4, 1.0 mM EGTA, 1.0 mM ethylen diamine tetraacetic acid (EDTA), protease, and phosphatase inhibitors) and total proteins concentration was determined using the Bio-Rad protein assay kit (Bio-Rad, Richmond, CA, United States). Thirty micrograms of proteins were resolved by SDS-PAGE, separated by electrophoresis, and blotted onto PVDF membrane (Amersham Bioscience, Amersham, United Kingdom). Membranes were incubated with specific antibodies against cAMP response element-binding protein (CREB) (1:200; catalog \#sc-240; Santa Cruz Biotechnology, CA, United States), brain-derived neurotrophic factor (BDNF) (1:200; catalog \#sc-65514; Santa Cruz Biotechnology), or nerve growth factor (NGF) (1:500; catalog \#MA5-32067; Invitrogen, Waltham, MA, United States). Equal loading of protein was assessed on stripped blots by immunodetection of β-actin (1:500; Abcam, Cambridge, MA, United States). For all primary antibodies, a peroxidase-conjugated goat anti-rabbit immunoglobulin G secondary antibody was used at concentration of 1:10,000 (catalog \#G-21234; Pierce, Chester, United Kingdom). Signals were detected using Amersham ECL Plus Western Blotting Detection Reagents (Amersham Bioscience). Computer-assisted densitometry (UN-SCAN-IT gel version 6.1; Silk Scientific, Inc., Orem, UT, United States) was used to perform semi-quantitative analysis of protein expression detected by immunoblotting. Different times of exposure were used for each blot. β-actin signal was used to normalize protein levels. Integrated density values were expressed as a percentage of densitometric levels using arbitrary densitometric units ([@B45]).

Real Time-Quantitative Polymerase Chain Reaction (RT-qPCR) {#S2.SS7}
----------------------------------------------------------

Total RNA was isolated with Trizol Reagent (Invitrogen) according to the manufacturer's protocol. Five micrograms of RNA from each sample were reversely transcribed using High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, United States). Generated cDNA was used as a template for RT-qPCR analysis. Briefly, for each reaction, 4 μl of cDNA in a total volume of 50 μl were used. 7300 Sequence Detection System apparatus (Applied Biosystems) was managed to quantitatively compare the mRNA levels; 20X target primer and probe (BDNF: HS02718934; NGF: HS00171458; CREB: HS00231713) were processed, and human β-actin (Cod.4326315E) was used as a house-keeping gene (Thermo Fisher Scientific). RT-qPCR was done in duplicate with 2 × TaqMan Universal PCR Master Mix. The thermal cycling conditions were as following: 10′ at 25°C, 120′ at 37°C, and then hold at 4°C. The comparative cycle threshold (Ct) procedure (Applied Biosystems) was used to analyze the data by generating relative values of target cDNA level. Relative quantification (RQ) was expressed as fold change over control, and calculated by the ΔΔCt method, with control samples as calibrators.

Statistical Analysis {#S2.SS8}
--------------------

For NanoString analysis, fold change (FC) expression changes between two groups were calculated by using nSolver v2.5 (NanoString Technologies) ratio data, based on normalized count data. *p* values between two groups were generated using a two-tailed t-test. Statistical analysis was done through Significance of Microarrays Analysis^[3](#footnote3){ref-type="fn"}^, using a *p* value based on 100 permutations; imputation engine: K-nearest neighbors (10 neighbors); false discovery rate (FDR) \<0.05. Quantitative RT-qPCR microRNA expression was assessed using SDS v2.4 software (Thermo Fisher Scientific) and analyzed using GraphPad Prism version 8.3.0. Results are expressed as mean ± standard deviation (SD). Receiver operating characteristic (ROC) analysis was used to assess the performance of miRNA as a binary expression status in symptomatic and asymptomatic carriers of TTRv. The area under the ROC curve (AUC) was also determined. Statistical multiple comparison between groups was performed by Kruskal-Wallis non-parametric ANOVA test. Comparison between groups was performed by Mann-Whitney test for unpaired non-parametric data. A level of significance of *p* \< 0.05 was considered.

Results {#S3}
=======

Among up to 800 biologically relevant miRNAs, 33 miRNAs were found significantly up-regulated and 48 down-regulated in the serum of ATTRv patients versus HC. Nine miRNAs were significantly up-regulated and 30 down-regulated in ATTRv patients versus CMT patients. With the aim to find differences between ATTRv patients versus asymptomatic carriers of TTRv, expression analysis led to identify 19 miRNAs significantly up-regulated and 38 miRNAs down-regulated in patients versus asymptomatic carriers. Twelve out of the 19 upregulated miRNAs had a fold increase higher than 100 ([Table 2](#T2){ref-type="table"}; GEO Series accession number [GSE149665](GSE149665)).

###### 

Differentially expressed miRNAs.

                                                     ATTRv patients vs HC   ATTRv patients vs CMT patients   ATTRv patients vs TTRv carriers                      
  -------------------------------------------------- ---------------------- -------------------------------- --------------------------------- -------- --------- -------------
  hsa-let-7d-5p                                      2.61                   0.003                            --                                --       1.38      0.02
  hsa-let-7i-5p                                      2.21                   0.002                            --                                --       --50.13   2.51E-09
  hsa-miR-10a-5p                                     --                     --                               --1.43                            0.01     --        --
  hsa-miR-15a-5p                                     --                     --                               --                                --       --1.54    0.02
  hsa-miR-19a-3p                                     --2.43                 0.0006                           --                                --       --        --
  hsa-miR-20a-5p + hsa-miR-20b-5p                    3.09                   0.0006                           --                                --       --        --
  hsa-miR-21-5p                                      3.5                    0.001                            2.34                              0.006    77.57     0.0001
  hsa-miR-22-3p                                      2.28                   0.003                            --                                --       --        --
  hsa-miR-25-3p                                      --2.03                 0.005                            --                                --       --        --
  hsa-miR-26b-5p                                     2.6                    0.001                            --                                --       2.26      0.0008
  hsa-miR-28-5p                                      --                     --                               2.68                              0.0001   --        --
  hsa-miR-30a-5p                                     --2.38                 0.01                             --                                --       --        --
  hsa-miR-33a-5p                                     --2.42                 0.0005                           --                                --       --        --
  hsa-miR-34a-5p                                     1.74                   0.03                             --                                --       106.74    0.00008
  hsa-miR-93-5p                                      --2.31                 0.001                            --                                --       --        --
  hsa-miR-96-5p                                      1.98                   0.03                             --                                --       --75.21   0.00000253
  hsa-miR-107                                        1.84                   0.0006                           --                                --       104.9     1.69E-08
  hsa-miR-124-3p                                     --2.37                 0.002                            --                                --       --        --
  hsa-miR-125a-3p                                    2.79                   0.0006                           --                                --       --        --
  hsa-miR-126-3p                                     --                     --                               --3.32                            0.001    --        --
  hsa-miR-132-3p                                     --2.09                 0.01                             --                                --       --        --
  hsa-miR-133b                                       --2.22                 0.001                            --                                --       --        --
  hsa-miR-138-5p                                     --                     --                               --1.85                            0.01     --        --
  hsa-miR-141-3p                                     --2.54                 0.0004                           --                                --       --        --
  hsa-miR-142-3p                                     --                     --                               --                                --       --2.25    0.003
  hsa-miR-144-3p                                     --2.15                 0.001                            --7.97                            0.0001   --        --
  hsa-miR-146a-5p                                    1.71                   0.01                             --                                --       --50.56   0.000000411
  hsa-miR-146b-5p                                    --                     --                               --2.05                            0.006    --        --
  hsa-miR-147a                                       --2.61                 0.001                            --                                --       --        --
  hsa-miR-150-5p                                     1.6                    0.02                             1.7                               0.03     109.23    0.00000111
  hsa-miR-181a-5p                                    --                     --                               --1.61                            0.003    --        --
  hsa-miR-181b-2-3p                                  --                     --                               --2.23                            0.0006   --        --
  hsa-miR-184                                        --                     --                               --                                --       --50.41   0.00000111
  hsa-miR-188-5p                                     --1.78                 0.001                            --1.87                            0.001    --        --
  hsa-miR-190a-3p                                    --1.91                 0.004                            --                                --       --        --
  hsa-miR-196a-5p                                    --                     --                               --1.77                            0.001    --        --
  hsa-miR-199a-3p + hsa-miR-199b-3p                  --2.68                 0.008                            --                                --       --        --
  hsa-miR-200a-3p                                    --                     --                               --1.69                            0.0003   --        --
  hsa-miR-206                                        1.58                   0.008                            --                                --       --50.33   0.00000183
  hsa-miR-208b-3p                                    2                      0.0004                           --                                --       68.44     0.0000031
  hsa-miR-210-3p                                     --2.15                 0.003                            --                                --       --        --
  hsa-miR-215-5p                                     2.13                   0.006                            --                                --       101.96    0.000000688
  hsa-miR-216a-5p                                    --1.74                 0.002                            --                                --       --        --
  hsa-miR-216b-5p                                    --                     --                               --1.92                            0.0005   --        --
  hsa-miR-219b-3p                                    --2.43                 0.0002                           --                                --       --53.14   0.00000127
  hsa-miR-223-3p                                     1.98                   0.002                            --                                --       --        --
  hsa-miR-224-5p                                     --                     --                               --1.37                            0.006    --        --
  hsa-miR-302e                                       --2.18                 0.003                            --                                --       --50.21   0.00000535
  hsa-miR-320a                                       --2.14                 0.003                            --                                --       --        --
  hsa-miR-320e                                       --2.33                 0.02                             --                                --       --        --
  hsa-miR-323b-3p                                    --5.09                 0.0008                           --2.1                             0.0002   --70.23   0.000002
  hsa-miR-328-5p                                     2.52                   0.002                            --                                --       --        --
  hsa-miR-335-5p                                     2.04                   0.009                            --                                --       --        --
  hsa-miR-339-5p                                     --                     --                               --1.8                             0.0005   --        --
  hsa-miR-363-5p                                     1.81                   0.04                             --                                --       65.44     0.0001
  hsa-miR-376a-3p                                    --                     --                               --1.92                            0.04     --        --
  hsa-miR-378d                                       --                     --                               --1.95                            0.01     --        --
  hsa-miR-378i                                       2.2                    0.0001                           --                                --       --70.11   0.000006
  hsa-miR-411-5p                                     --2.14                 0.02                             --                                --       --2.01    0.004
  hsa-miR-422a                                       --2.42                 0.0002                           --                                --       --        --
  hsa-miR-450a-2-3p                                  --2.24                 0.0005                           --                                --       --50.19   0.00001
  hsa-miR-452-5p                                     --2.27                 0.002                            --                                --       --        --
  hsa-miR-495-3p                                     1.79                   0.03                             --                                --       --50.28   0.00006
  hsa-miR-497-5p                                     2.27                   0.01                             --                                --       51.81     0.00000106
  hsa-miR-514b-5p                                    --                     --                               --                                --       --52.12   0.00000956
  hsa-miR-518c-3p                                    --3.17                 0.001                            --                                --       --        --
  hsa-miR-518d-3p                                    --2.87                 0.0002                           --                                --       --        --
  hsa-miR-526a + hsa-miR-518c-5p + hsa-miR-518d-5p   --                     --                               --                                --       --71.41   0.00000121
  hsa-miR-548ad-3p                                   --1.74                 0.0008                           --2.06                            0.0009   --71.2    0.000000891
  hsa-miR-548ah-5p                                   --2.04                 0.01                             --                                --       --51.94   0.00006
  hsa-miR-548ar-3p                                   --1.76                 0.0008                           --                                --       --50.16   0.00007
  hsa-miR-566                                        --                     --                               --                                --       --70.31   0.000000465
  hsa-miR-575                                        2.02                   0.01                             3.24                              0.001    108.57    0.0001
  hsa-miR-584-5p                                     --                     --                               2.62                              0.008    --        --
  hsa-miR-585-3p                                     1.76                   0.01                             --                                --       --1.7     0.0003
  hsa-miR-587                                        2.44                   0.006                            --                                --       102.39    0.00003
  hsa-miR-593-3p                                     --                     --                               --1.89                            0.0001   --        --
  hsa-miR-598-3p                                     --2.02                 0.002                            --                                --       --        --
  hsa-miR-603                                        2.49                   0.03                             --                                --       --        --
  hsa-miR-607                                        --2.11                 0.01                             --                                --       --        --
  hsa-miR-612                                        --2.06                 0.0002                           --1.71                            0.0001   --        --
  hsa-miR-637                                        --2                    0.0006                           --                                --       --        --
  hsa-miR-663a                                       --                     --                               --                                --       --72.96   0.00000086
  hsa-miR-758-5p                                     --2.72                 0.01                             --                                --       --        --
  hsa-miR-802                                        --                     --                               --                                --       --71.52   0.00000551
  hsa-miR-873-3p                                     --2.44                 0.005                            --1.43                            0.0004   --71      8.67E-08
  hsa-miR-876-3p                                     1.53                   0.009                            --                                --       121.29    0.00001
  hsa-miR-877-5p                                     --2.03                 0.0005                           --                                --       117.34    0.0001
  hsa-miR-887-5p                                     8.68                   0.0002                           --                                --       --        --
  hsa-miR-889-3p                                     1.75                   0.001                            2.11                              0.0002   112.77    9.41E-14
  hsa-miR-891b                                       --1.51                 0.001                            --                                --       66.38     0.000000747
  hsa-miR-922                                        --2.21                 0.03                             --                                --       --57.32   0.00000241
  hsa-miR-933                                        --                     --                               --1.51                            0.003    --        --
  hsa-miR-936                                        --2.09                 0.0001                           --                                --       --50.35   0.000000841
  hsa-miR-941                                        --                     --                               --1.85                            0.002    --        --
  hsa-miR-1185-1-3p                                  --2.1                  0.005                            --                                --       --        --
  hsa-miR-1185-2-3p                                  --2.8                  0.0001                           --                                --       --2.32    0.003
  hsa-miR-1261                                       --2.36                 0.01                             --                                --       --        --
  hsa-miR-1268b                                      --2.21                 0.0005                           --                                --       --53.52   0.000000168
  hsa-miR-1277-3p                                    2.75                   0.01                             --                                --       --        --
  hsa-miR-1279                                       3.07                   0.006                            --                                --       119.18    0.00001
  hsa-miR-1285-3p                                    --                     --                               --                                --       --2.18    0.003
  hsa-miR-1287-5p                                    1.8                    0.009                            2.53                              0.002    104.7     0.000000611
  hsa-miR-1296-3p                                    5.93                   0.001                            --                                --       --61.1    4.61E-17
  hsa-miR-1304-3p                                    --                     --                               --2.05                            0.0003   --        --
  hsa-miR-1304-5p                                    --2.28                 0.001                            2.03                              0.01     102.09    0.0005
  hsa-miR-1322                                       --2.37                 0.006                            --                                --       --        --
  hsa-miR-1827                                       --                     --                               1.73                              0.03     --1.96    0.001
  hsa-miR-1972                                       --                     --                               --                                --       --52.55   9.26E-08
  hsa-miR-2117                                       --                     --                               --2.1                             0.03     --        --
  hsa-miR-3168                                       --                     --                               --                                --       --73.46   7.01E-08
  hsa-miR-3614-5p                                    --                     --                               --                                --       --1.81    0.0004
  hsa-miR-3615                                       --                     --                               --1.86                            0.002    --        --
  hsa-miR-3928-3p                                    --                     --                               --1.59                            0.0004   --        --
  hsa-miR-4421                                       --                     --                               --1.5                             0.02     --59.22   0.00000135
  hsa-miR-4454 + hsa-miR-7975                        --2.17                 0.005                            --                                --       --2.2     0.04
  hsa-miR-4516                                       --                     --                               --                                --       --1.67    0.01
  hsa-miR-4536-5p                                    --2.03                 0.001                            --                                --       --        --
  hsa-miR-4787-5p                                    --                     --                               --                                --       --70.66   0.000000199
  hsa-miR-5010-3p                                    --                     --                               --1.52                            0.002    --        --
  hsa-miR-6720-3p                                    --                     --                               --2.1                             0.0002   --        --
  hsa-miR-6721-5p                                    --                     --                               --1.54                            0.0006   --        --

Bioinformatic analysis of upregulated miRNAs found in ATTRv patients vs TTRv carriers revealed that the target genes were involved in a variety of cellular functions. The top significantly related GO terms are listed in [Table 3](#T3){ref-type="table"}. The KEGG analysis showed the involvement of the upregulated target genes in important pathways such as axon guidance, the mitogen-activated protein kinase (MAPK) cascade, and the forkhead box O (FOXO) family of transcription factors, the last two being involved in proliferation, apoptosis, differentiation, and cell-cycle control ([Table 4](#T4){ref-type="table"}).

###### 

GO analysis of targets of upregulated miRNAs found in ATTRv patients vs TTRv carriers.

  Category              Term                                                                Count   *p*-value    FDR
  --------------------- ------------------------------------------------------------------- ------- ------------ -----------
  Biological process    GO:0007399∼nervous system development                               175     7.89E-12     1.75E-08
                        GO:0065008∼regulation of biological quality                         174     6.25E-11     6.78E-09
                        GO:0023051∼regulation of signaling                                  176     4.12E-12     6.81E-09
                        GO:0007167∼enzyme linked receptor protein signaling pathway         105     2.33E-11     4.26E-08
                        GO:0010604∼positive regulation of macromolecule metabolic process   198     2.72E-11     5.34E-08
                        GO:0010646∼regulation of cell communication                         148     2.22E-09     2.23E-09
  Molecular function    GO:0070491∼repressing transcription factor binding                  124     2.54E-11     6.57E-09
                        GO:0061659∼ubiquitin-like protein ligase activity                   118     3.12E-10     3.21E-09
                        GO:0019899∼enzyme binding                                           122     0.00000179   1.18E-09
                        GO:0019904∼protein domain specific binding                          108     0.00000358   1.26E-08
                        GO:0005057∼receptor signaling protein activity                      48      2.98E-08     0.0000451
                        GO:0140096∼catalytic activity, acting on a protein                  57      3.01E-08     3.23E-09
  Cellular components   GO:0070062∼extracellular exome                                      178     2.98E-11     2.88E-09
                        GO:0044451∼nucleoplasm part                                         122     0.00000184   1.21E-09
                        GO:0044424∼intracellular part                                       52      0.00000181   1.18E-08
                        GO:0005057∼receptor signaling protein activity                      68      2.11E-08     0.0000374

###### 

KEGG pathway analysis of targets of upregulated miRNAs found in ATTRv patients vs TTRv carriers.

  KEGG pathways                      Count   *p*-value   FDR
  ---------------------------------- ------- ----------- -----------
  hsa04360: Axon guidance            78      0.0000083   0.0000531
  hsa04010: MAPK signaling pathway   58      0.0000287   0.0000019
  hsa04068: FoxO signaling pathway   62      0.0000482   0.0000021

After a database search and literature review of the twelve most up-regulated miRNAs in ATTRv patients versus asymptomatic carriers of TTRv, miR-150-5p was selected for further validation. miR-150-5p expression was measured by RT-qPCR in the serum of n. 24 ATTRv patients and n. 23 asymptomatic carriers of TTRv ([Table 1](#T1){ref-type="table"}). The results revealed that miR-150-5p was significantly up-regulated in patients compared with asymptomatic carriers ([Figure 1A](#F1){ref-type="fig"} and [Supplementary Table S1](#TS1){ref-type="supplementary-material"}). ROC curve analysis indicated that miR-150-5p was a valuable serum biomarker for differentiating with an AUC of 0.9728 (95% CI: 0.9285--1.000). At the cutoff value of 2.395, sensitivity and specificity were 95.8 and 95.6%, respectively ([Figure 1B](#F1){ref-type="fig"}).

![Expression levels of circulating miR-150-5p in 23 asymptomatic TTRv carriers and 24 ATTRv patients **(A)**. Receiver operating characteristic (ROC) curve analysis of miR-150-5p **(B)**. AUC resulted 0.9728 (95% CI: 0.9285--1.000). At the cutoff value of 2.395, sensitivity and specificity were 95.8 and 95.6%, respectively.](fnmol-13-00102-g001){#F1}

Since in ATTRv mutated transthyretin aggregates and forms amyloid fibrils in target organs, chiefly the peripheral nervous system and the heart, the expression of three regulators of neuronal growth, differentiation, survival and regeneration, such as CREB, BDNF and NGF, which are also involved in cardiac dysfunction, were investigated in human SCs cultures transfected by miR-150-5p mimic/inhibitor. Treatment with miR-150-5p mimic markedly increased the miR-150-5p expression by around 30-fold when compared to control (*p* \< 0.0001), whereas treatment with miR-150-5p inhibitor suppressed its expression (*p* \< 0.0001) ([Figure 2](#F2){ref-type="fig"}). CREB protein and mRNA levels decreased after transfection of miR-150-5p mimic by almost 6-fold (*p* \< 0.0001) and almost 4-fold (*p* \< 0.0001), respectively ([Figure 3](#F3){ref-type="fig"}). BDNF protein and mRNA levels were decreased after transfection of miR-150-5p mimic by almost 4-fold (*p* \< 0.0001) and almost 4-fold (*p* \< 0.0001), respectively ([Figure 4](#F4){ref-type="fig"}). NGF protein and mRNA levels reduced after transfection of miR-150-5p mimic by 2-fold (*p* \< 0.0001) and 2-fold (*p* \< 0.0001), respectively ([Figure 5](#F5){ref-type="fig"}). Data from SCs culture experiments are listed in [Supplementary Table S2](#TS2){ref-type="supplementary-material"}.

![Transfection of miR-150-5p mimic and inhibitor into human primary Schwann cells and its effect on miR-150-5p expression. Non-parametric ANOVA Kruskal-Wallis test *p* \< 0.0001.](fnmol-13-00102-g002){#F2}

![CREB protein **(A)** and mRNA **(B)** levels in transfected human primary Schwann cells. **(A)** Lower panel shows graph with quantitative data; upper panel shows representative autoradiograms. Independent experiments were performed in triplicate. Non-parametric ANOVA Kruskal-Wallis test *p* \< 0.0001 in both experiments.](fnmol-13-00102-g003){#F3}

![BDNF protein **(A)** and mRNA **(B)** levels in transfected human primary Schwann cells. **(A)** Lower panel shows graph with quantitative data; upper panel shows representative autoradiograms. Independent experiments were performed in triplicate. Non-parametric ANOVA Kruskal-Wallis test *p* \< 0.0001 in both experiments.](fnmol-13-00102-g004){#F4}

![NGF protein **(A)** and mRNA **(B)** levels in transfected human primary Schwann cells. **(A)** Lower panel shows graph with quantitative data; upper panel shows representative autoradiograms. Independent experiments were performed in triplicate. Non-parametric ANOVA Kruskal-Wallis test *p* \< 0.0003 and *p* \< 0.0005, respectively.](fnmol-13-00102-g005){#F5}

Discussion {#S4}
==========

Protein TTR misfolding and tissue deposition of amyloid start many years before the appearance of the first symptoms in ATTRv ([@B5]; [@B2]). This phenomenon leads to the opportunity and the need to identify novel biomarkers to detect earlier phases of the disease and to permit prompter disease treatment. Since several studies have reported the presence of inflammation in ATTRv nerve biopsies, some inflammatory markers have been recently investigated in serum. TNF-α, IFN-β, IL-1β, IL-8, IL-10, and IL-33 were found increased in patients versus healthy controls, but high levels of IL-33, IL-1β, and IL-10 were already seen in stage 0 asymptomatic carriers. Although it is unclear whether such a pattern of inflammatory cytokines is primarily related to the disease pathogenesis or is a secondary effect of tissue damage or to circulating oligomers, it confirms that the body is reacting to the disease much before amyloid deposition or tissue damage take place ([@B6]).

Circulating miRNAs have been investigated in patients with ATTRv and wild type ATTR (ATTRwt) cardiomyopathy. Validation experiments led to the identification of up-regulated miR-339-3p only in ATTRwt but not in patients with heart failure of other origin or with ATTRv, supporting it as a potential candidate biomarker for ATTRwt ([@B11]). Our pilot study was performed with the main aim to distinguish miRNAs profile between stage 0 and stage 1--2 in subjects carrying a TTR mutation. We found many candidates deregulated in ATTRv patients versus healthy controls, versus CMT patients and versus asymptomatic carriers of TTRv. Our attention was drawn on 12 miRNAs significantly up-regulated with a fold increase higher than 100 in ATTRv patients versus asymptomatic TTRv carriers. Among them, we focused on miR-150-5p and aimed to validate our results and to look for possible pathomechanisms.

MiR-150-5p is expressed in many tissues, with greater distribution in pancreas, lymph nodes, spleen, vascular system, respiratory system, prostate, esophagus, kidney, thyroid, and also in peripheral nerves and myocardium ([@B29]). It regulates various immune cell functions via apoptosis, survival, and proliferation, controlling immune response and inflammatory cytokines, and also plays an important role in the pathogenesis of both solid and hematological cancers ([@B48]; [@B21]; [@B42]). No data are so far available in the literature about miR-150-5p expression either in different components of normal nerves, i.e., the axon-myelin unit, or in nerves and heart from ATTRv patients or animal models. The miR-150-5p up-regulation found in this study was tested in a larger separate validation cohort and ROC analysis allowed to confirm the discrimination ability of miR-150-5p to differentiate ATTRv patients from asymptomatic carriers of TTRv, with high sensitivity and specificity. Some studies have investigated the different ability of laboratory and instrumental tests to detect early heart involvement and predict clinical worsening in subjects carrying a TTRv but yet completely asymptomatic who have been serially followed-up ([@B15]; [@B19]; [@B34]). Similarly, the discovery of a non-invasive sensitive biomarker specific for ATTRv patients, as supported by present results, needs now to be further validated longitudinally in a large cohort of asymptomatic carriers of TTRv to identify the time of increased expression of serum miR-150-5p and to verify its possible capability to anticipate the appearance of clinical symptoms. If the latter will be confirmed, this could be a strong argument in favor of an early start of now available innovative treatments ([@B44]) in still asymptomatic carriers.

How increased expression of miR-150-5p could play a pathophysiological role in ATTRv is lacking in the scientific literature, although some findings have been reported regarding other neurodegenerative and cardiac diseases. Decreased plasma miR-150-5p levels have been found in patients with Alzheimer disease (AD) versus healthy controls ([@B30]). Increased levels were observed in hippocampal neurons of prion-infected mice and in synaptoneurosomes from prion-infected mouse forebrain, both at terminal stage of the disease ([@B32]; [@B10]). Evidences were provided that increased miR-150 levels found in Purkinje neurons of the mouse model of spinocerebellar ataxia type 1 may modulate disease pathogenesis by targeting the expression of RGS8 and VEGFA genes ([@B40]). Moreover, circulating miR-150 was up-regulated in workers with carbon disulfide neuropathy ([@B17]), and miR-150-5p down-regulated in patients with advanced heart failure ([@B43]). So, we decided to investigate the possible crosstalk between miR-150-5p and three different factors, CREB, BDNF, and NGF, whose roles in central and peripheral nervous systems and in the heart are known, using a cell culture model. Human primary SCs cultures were chosen as an easy model on the evidence of miR-150-5p expression in nerves ([@B29]). Although peripheral nerve involvement occurring in ATTRv is mainly an axonal type of neuropathy, SCs are known to participate with an active role during axonal degeneration, although through still poorly understood molecular and cellular mechanisms ([@B47]).

CREB has a multifaceted role in the nervous system, mostly in neurodevelopment, synaptic plasticity, and neuroprotection ([@B41]). Recent evidences have been presented supporting the possibility that a dysregulation of CREB signaling is associated to cerebral amyloidosis, formation of tangle-like structures and microglial clustering, and cognitive decline in AD and its animal model ([@B23]; [@B8]). Moreover, CREB protein family of transcription factors is involved in cardiac growth, ventricular remodeling, and heart failure ([@B25]; [@B27]; [@B49]).

BDNF plays a key role in neurogenesis and synaptic repair and is implicated in numerous neurodegenerative disorders ([@B9]). Low plasma BDNF levels have been found significantly associated with brain amyloid burden measured with Pittsburg Compound B in AD and mild cognitive impairment patients, supporting a pathogenic and a peripheral signature role of BDNF ([@B20]). Equally BDNF is a focal growth factor which regulates the response of cardiovascular system to acute and chronic injury, modulating contractility, neoangiogenesis, apoptosis and survival of cardiac myocytes, vascular muscle cells, and endothelial cells ([@B24]).

Finally, NGF is the firstly discovered and best characterized neurotrophic factor, able to stimulate neuronal growth and differentiation in central, peripheral, and sympathetic nervous systems ([@B14]; [@B4]). Likewise, NGF plays a role in cardiac physiopathology. Its levels increase following myocardial injury, most likely leading to sympathetic nerve sprouting, but decrease when heart failure develops, an event that may participate to defective innervation and cardiac failure ([@B16]).

MiRNAs are important post-transcriptional regulators which participate to axonal guidance in the central nervous system, and to proliferation and migration of SCs and axonal growth in the peripheral nervous system ([@B46]). Our SCs culture model allowed to demonstrate for the first time that miR-150-5p is a powerful negative regulator of CREB gene, BDNF gene, and, to a lesser extent, NGF gene expression, providing an additional basis for further investigations of their role in neurodegeneration and specifically in ATTRv pathogenesis.

This pilot study has some limits. One is the small sample size, but we have to consider that ATTRv amyloidosis is a rare disease and an exclusion criterion was the presence of concomitant major disease. Moreover, 12 miRNAs were found up-regulated with a fold increase higher than 100 in ATTRv patients versus asymptomatic TTRv carriers. However, we concentrated on one of them, miR-150-5p, in this study, with the aim to validate it and to look for associated pathophysiology. Nevertheless, all the others miRNAs have a translational potential and may point to future directions in the analysis of this emerging class of biomarkers. Furthermore, the biological basis of our observations in SCs culture needs to be confirmed in other experimental models.

In conclusion, identification of dysregulated miRNAs can help in understanding the complex pathomechamism underlying the development of ATTRv and related multisystemic pathology. The current results showed that some miRNAs are up-regulated and other down-regulated in stage 1-2 ATTRv patients versus stage 0 subjects. Serum level of miR-150-5p were able to well discriminate stage 1-2 versus stage 0. Our SCs culture model demonstrated that miR-150-5p may modulate the expression of CREB, BDNF and NGF genes, supporting their role in ATTRv pathogenesis. Further investigations on the role of circulating miR-150-5p to predict the shift of TTRv carriers from stage 0 to stage 1 are needed. Moreover, another future line of investigation should examine whether miR-150-5p circulating levels are responsive to the innovative treatments now available.

Data Availability Statement {#S6}
===========================

The datasets generated for this study are available on request to the corresponding author.

Ethics Statement {#S7}
================

The study was approved by Comitato Etico di Messina, AOU Policlinico "G. Martino", Messina, Italy. The patients/participants provided their written informed consent to participate in this study.

Author Contributions {#S8}
====================

GLV, M'HA, CR, RD, AT, GV, and AM contributed to the conception and design of the study. GLV, M'HA, FP, RO, MRu, LG, CB, MRa, RD, GV, and AM contributed to the acquisition and analysis of data. GLV, M'HA, FP, RO, MRu, LG, CB, MRa, CR, RD, AT, GV, and AM contributed to drafting the text and preparing the figures. All authors approved the final version.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** The present study was supported by a Research Grant to University of Messina from Pfizer Inc. Pfizer Inc. had no role in the study design, data analysis, and results interpretation of the present study.

<http://www.microrna.gr/tarbase>

<http://snf-515788.vm.okeanos.grnet.gr/>

<http://www.tm4.org>

Supplementary Material {#S10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fnmol.2020.00102/full#supplementary-material>

List of miRNAs expressed in the single subjects has been deposited in NCBI's Gene Expression Omnibus and is accessible through GEO Series accession number [GSE149665](GSE149665) (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc~=~GSE149665>).

###### 

Data from validation set.

###### 

Click here for additional data file.

###### 

Data from Schwann cells culture experiments.

###### 

Click here for additional data file.

[^1]: Edited by: Stefano Carlo Previtali, San Raffaele Scientific Institute (IRCCS), Italy

[^2]: Reviewed by: Kleopas A. Kleopa, The Cyprus Institute of Neurology & Genetics, Cyprus; John Svaren, University of Wisconsin--Madison, United States

[^3]: ^†^These authors share first authorship
